IL2 and cancer: Our previous findings showed that the cancer therapeutic function of IL2-expressing VACV in the 4T1 mouse model depends not only on the backbone virus strain (Lister strain 1.1.1 vs Copenhagen strain) but also on the promoter used to drive the expression of the payload (p7.5 promoter vs Psyn (E/L) promoter) (Supplementary Figure S3).